Myélome multiple indolent

作者: G. Fouquet , S. Guidez , C. Herbaux , H. Demarquette , X. Leleu

DOI: 10.1016/J.REVMED.2013.08.004

关键词:

摘要: Resume Le myelome multiple indolent ( smoldering myeloma [SMM]) est une proliferation plasmocytaire asymptomatique qui presente un risque d’evolution vers superieur a la gammapathie monoclonale de signification indeterminee monoclonal gammopathy of undetermined significance [MGUS]). Il faut donc differencier le fois MGUS progression bien plus faible, mais egalement du symptomatique reste pathologie incurable et necessite traitement specifique. La question cruciale dans cadre prise en charge des myelomes multiples indolents celle benefice possible d’une intervention therapeutique precoce, pourrait permettre retarder multiple, limiter complications graves liees cette progression, voire d’obtenir guerison. Ce precoce ne peut pas etre propose l’ensemble patients porteurs d’un SMM, par definition asymptomatiques, chez toxicite rendre difficilement justifiable potentiel obtenu. difficulte d’arriver cibler diagnostic les ayant SMM haut evolutif, l’aide d’examens disponibles routine, facon suffisamment fiable pour legitimer sanction decouler. Rappelons cependant qu’a l’heure actuelle, dehors d’etudes randomisees, l’abstention regle indolent.

参考文章(30)
A Riccardi, O Mora, C Tinelli, D Valentini, S Brugnatelli, R Spanedda, A De Paoli, L Barbarano, M Di Stasi, M Giordano, C Delfini, G Nicoletti, C Bergonzi, E Rinaldi, L Piccinini, E Ascari, Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study British Journal of Cancer. ,vol. 82, pp. 1254- 1260 ,(2000) , 10.1054/BJOC.1999.1087
F. Wisløff, P. Andersen, T. R. Andersson, E. Brandt, C. Eika, K. Fjaestad, T. Grønvold, B. Holm, K. Løvåsen, G. E. Tjønnfjord, Incidence and follow-up of asymptomatic multiple myeloma. The myeloma project of health region I in Norway. II. European Journal of Haematology. ,vol. 47, pp. 338- 341 ,(2009) , 10.1111/J.1600-0609.1991.TB01857.X
R. García-Sanz, J. Bladé, J. Almeida, M. J. Moro, M. Rozman, M. González, J. Hernández, J. F. San Miguel, C. López-Berges, D. Caballero, A. Orfao, L. Escribano, M. Ocqueteau, Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. American Journal of Pathology. ,vol. 152, pp. 1655- 1665 ,(1998)
T. Facon, J.F. Menard, J.L. Michaux, L. Euller-Ziegler, J.F. Bernard, B. Grosbois, A. Daragon, I. Azais, Y. Courouble, G. Kaplan, J.P. Laporte, A. De Gramont, B. Duclos, A. Leonard, P. Mineur, A. Delannoy, J.P. Jouet, F. Bauters, M. Monconduit, , Prognostic factors in low tumour mass asymptomatic multiple myeloma: A report on 91 patients American Journal of Hematology. ,vol. 48, pp. 71- 75 ,(1995) , 10.1002/AJH.2830480201
Meletios A. Dimopoulos, Angela Moulopoulos, Terry Smith, Kay B. Delasalle, Raymond Alexanian, Risk of disease progression in asymptomatic multiple myeloma The American Journal of Medicine. ,vol. 94, pp. 57- 61 ,(1993) , 10.1016/0002-9343(93)90120-E
Robert A. Kyle, Ellen D. Remstein, Terry M. Therneau, Angela Dispenzieri, Paul J. Kurtin, Janice M. Hodnefield, Dirk R. Larson, Matthew F. Plevak, Diane F. Jelinek, Rafael Fonseca, Lee Joseph Melton, S. Vincent Rajkumar, Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. The New England Journal of Medicine. ,vol. 356, pp. 2582- 2590 ,(2007) , 10.1056/NEJMOA070389
Robert A. Kyle, Philip R. Greipp, Smoldering Multiple Myeloma New England Journal of Medicine. ,vol. 302, pp. 1347- 1349 ,(1980) , 10.1056/NEJM198006123022405
Angela Dispenzieri, Robert A. Kyle, Jerry A. Katzmann, Terry M. Therneau, Dirk Larson, Joanne Benson, Raynell J. Clark, L. Joseph Melton, Morie A. Gertz, Shaji K. Kumar, Rafael Fonseca, Diane F. Jelinek, S. Vincent Rajkumar, Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma Blood. ,vol. 111, pp. 785- 789 ,(2008) , 10.1182/BLOOD-2007-08-108357
Martin Hjorth, Louise Hellquist, Erik Holmberg, Bengt Magnusson, Stig Rödjer, Jan Westin, Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I — A randomized study European Journal of Haematology. ,vol. 50, pp. 95- 102 ,(2009) , 10.1111/J.1600-0609.1993.TB00148.X
F. Ong, J. Hermans, E. M. Noordijk, P. W. Wijermans, P. J Seelen, W De Kieviet, W. B. J Gerrits, Ph. M Kluin, J. C. Kluin-Nelemans, , A population‐based registry on paraproteinaemia in the Netherlands British Journal of Haematology. ,vol. 99, pp. 914- 920 ,(1997) , 10.1046/J.1365-2141.1997.4943298.X